Naslov
Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?

Autori
Ćelap, Ivana ; Margetić, Sandra ; Mihić, Roman ; Obuljen, Jasna ; Linarić, Irena ; Leniček Krleža, Jasna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Res Pract Thromb Haemost / Cushman, Mary - Medford : John Wiley & Sons, 2020

Skup
Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH 2020)

Mjesto i datum
Online, 12.07.2020. - 14.07.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
anti Xa assay, apixaban, adolescents
(antiepileptics, platelet aggregation)

Sažetak
Background: Although clinical application of apixaban does not require coagulation monitoring, there are clinical situations in which measurement of drug concentration should be performed. Anti-activated factor Xa (anti- FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. Aims: To assess whether commercial low molecular weight heparin (LMWH)-calibrated anti-FXa assay can be used for assessing anticoagulant effect of apixaban in adolescents. Methods: LMWH-calibrated anti-FXa method (Innovance heparin, Siemens Healthineers, Germany) was used for measurement of LMWH anti- FXa activity. Innovance heparin (Siemens Healthineers, Germany) calibrated with apixaban calibrators (Hyphen BioMed, France) was used for quantitative determination of apixaban concentration. Agreement between LMWH and apixaban calibrated anti-FXa assays was tested using kappa statistics whereas receiver operating characteristics (ROC) analysis was performed for LMWH therapeutic range. The study was funded by the Croatian Science Foundation as part of the research project IP-2016-06- 8208. Results: In 36 plasma samples of 11 adolescents (13-22 years), concentrations of apixaban ranged from 20 ng/mL to 267 ng/mL (median 94 ng/mL). LMWH anti-FXa activity ranged from 0.11 to 1.50 (upper LMWH measuring range) (median 0.68 IU/mL) (Table 1). Inter-rater aggrement analysis showed poor agreement (κ=0.16 ; 95%CI – 0.0327 to 0.3386) between therapeutic range of LMWH-calibrated anti-FXa activity and clinically relevant apixaban concentrations (>30 ng/mL) (Table 2). ROC analysis showed that only apixaban concentrations between 57 and 121 ng/mL could be expected with certainty within therapeutic range for LMWH anti-FXa activity. Cut-off value for LMWH anti-FXa activity for apixaban concentrations < 30 ng/mL is 0.12 IU/mL. Conclusions: LMWH anti-FXa activity assay is not appropriate method for quantitative estimation of apixaban concentration and should not be used as an interchangeable method. Quantitative measurement of apixaban concentration should be performed in all clinical situations.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA